Medical Oncologist
PIK3CA mutation · HR+ breast cancer
PIK3CA Mutation in Breast Cancer: — Alpelisib and What to Expect
If your breast cancer is hormone-receptor-positive and HER2-negative, testing for a PIK3CA mutation changes which treatment your oncologist recommends. This page explains what the mutation is, how alpelisib works alongside fulvestrant, and what to expect on treatment.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- A gene, not a cancer type — PIK3CA is a gene. Finding a mutation in it does not change your diagnosis — it changes which treatment is most likely to work.
- Testing decides eligibility — Alpelisib is only recommended when the PIK3CA mutation is confirmed in tumour tissue or blood.
- A combination regimen — Alpelisib is always given alongside fulvestrant, not on its own.
- Blood sugar needs monitoring — Hyperglycaemia is the most common side effect of alpelisib. Regular blood tests are needed from the start.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
If your breast cancer is hormone-receptor-positive and HER2-negative, a PIK3CA mutation in the tumour tissue decides whether alpelisib — a PI3K-alpha inhibitor — is the right targeted treatment. NCCN and ESMO guidance supports alpelisib combined with fulvestrant when this mutation is confirmed in your results.
What is a PIK3CA mutation?
PIK3CA is a gene that instructs cells to produce an enzyme called PI3K-alpha. In its normal state, this enzyme helps regulate cell growth in a controlled way.
When PIK3CA is mutated, the enzyme stays permanently switched on. This drives tumour growth through a pathway that does not depend on oestrogen alone — which is why standard hormone therapy often stops being enough once this mutation is active.
Detecting the mutation does not mean your prognosis has worsened. It gives your oncologist precise information about which pathway is driving the cancer, and which drug is designed to block it.
Which medicines are used when PIK3CA mutation is confirmed?
Two medicines work together in this regimen. Alpelisib is a daily tablet and a PI3K-alpha inhibitor — it directly blocks the overactive enzyme the mutated gene produces. Fulvestrant is a monthly injection that degrades the oestrogen receptor, removing the signal that hormone-receptor-positive tumours rely on.
NCCN and ESMO recommend this combination for postmenopausal women and men with HR-positive, HER2-negative advanced breast cancer who have a confirmed PIK3CA mutation and whose disease has progressed on or after prior endocrine therapy.
Alpelisib is selective for the alpha form of PI3K — the form that PIK3CA mutation activates. This selectivity is intentional: it aims to target the cancer's growth signal while limiting effect on other PI3K forms in healthy tissue.
What happens after a PIK3CA mutation is found?
Mutation confirmed in your report
Your oncologist receives the biomarker result from your biopsy tissue or liquid biopsy and confirms whether a PIK3CA mutation is present and which variant it is.
Baseline blood tests done
Before starting alpelisib, your team checks blood sugar, HbA1c, liver function and full blood count. These results inform the starting dose and any monitoring arrangements.
Treatment plan discussed
Your oncologist explains the regimen — alpelisib tablets taken at home daily, fulvestrant injections given at the clinic monthly — and what to watch for in the first weeks.
Treatment begins
Both medicines start on the agreed date. Your team will schedule early blood sugar checks and confirm who to contact if you notice a side effect between clinic visits.
Ongoing monitoring
Blood sugar is checked frequently at first, then at regular intervals. Scans are done periodically to assess how the cancer is responding and whether the regimen should continue.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
What to report to your team while on alpelisib
- Increased thirst or frequent urinationThese can signal that blood sugar has risen. Call your team the same day.
- A new skin rashRash is common and manageable when caught early. Tell your team at first sign.
- Diarrhoea that does not settle in 24 hoursMild loose motions are expected. Persistent or worsening diarrhoea needs a call.
- Mouth soresStomatitis can affect eating. Your team can suggest a mouthwash — do not ignore it.
- A rash that blisters, peels, or spreads widelyThis needs same-day urgent review, not wait-and-see.
- Any symptom you are unsure aboutIf something feels wrong and you do not know if it is treatment-related, call rather than waiting for the next appointment.
Questions families ask about PIK3CA treatment
What exactly does each drug in this regimen do?
Alpelisib is a PI3K-alpha inhibitor. It blocks the enzyme that the mutated PIK3CA gene overactivates, cutting off a key growth signal inside the tumour cell. It is taken as a daily tablet at home. Fulvestrant is an oestrogen receptor degrader — it physically breaks down the receptor that hormone-sensitive tumours depend on, rather than just blocking it the way some earlier hormone treatments do. It is given as a monthly injection at the clinic. The two drugs attack the cancer through different mechanisms simultaneously, which is why the combination is recommended rather than either drug alone.
Why is blood sugar monitoring so important with alpelisib?
The PI3K-alpha pathway plays a role in how the body responds to insulin. When alpelisib blocks this pathway in tumour cells, it also affects how insulin works in healthy tissue, which can cause blood sugar to rise. According to NCCN guidance, hyperglycaemia is among the most common and clinically significant side effects of alpelisib. Patients with pre-existing diabetes or raised blood sugar at baseline need especially close monitoring and may need their diabetes treatment adjusted before alpelisib begins. Your oncologist may recommend a protective medicine from the very first dose.
Does PIK3CA mutation status change over time?
A mutation result reflects the tumour at the time that sample was taken. Tumours can evolve, and a second biopsy or liquid biopsy taken later may show a different picture. This is one reason oncologists sometimes repeat testing when the cancer progresses, rather than relying only on an earlier result. Liquid biopsy — a blood test that detects tumour DNA shed into the bloodstream — can track the mutation without a new tissue procedure each time, making monitoring more practical for some patients.
What happens if the PIK3CA mutation is not found?
Not finding the mutation means alpelisib is not recommended for you, because the clinical evidence is specific to patients whose tumours carry this mutation. This is not a statement about how advanced the cancer is or about your overall outlook — it means a different pathway is driving the cancer, and a treatment matched to that pathway will be chosen. Other targeted options, such as CDK4/6 inhibitors, may still be relevant depending on your treatment history. Your oncologist will explain which option fits your specific situation.
Is alpelisib available in India?
Alpelisib is available for this indication through specialist oncology centres in India. Access and cost vary between centres, and some pharmaceutical companies have patient-support or managed-access programmes that your treating team can advise on. CION coordinates this discussion as part of the treatment-planning process at the time of diagnosis. If you are seen at a CION centre, ask your oncologist and the pharmacy team about current availability at your specific location.
Did you know?
In some patients, a PIK3CA mutation can be detected from a blood sample alone — without a repeat biopsy — using a test that looks for tumour DNA circulating in the bloodstream.
This liquid biopsy approach is increasingly used when a tissue procedure would be difficult or when monitoring is needed between scans, though tissue testing remains preferred when it is safely accessible.
Source: ESMO Clinical Practice Guidelines for Advanced Breast Cancer
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
What is a PIK3CA mutation in breast cancer?
PIK3CA is a gene that controls a growth enzyme called PI3K-alpha. When this gene is mutated, the enzyme stays switched on and drives the tumour to grow independently of oestrogen — which is why standard hormone therapy alone often stops being enough. Finding this mutation does not mean the cancer is more dangerous; it means your oncologist now knows which pathway to target, and alpelisib is the drug designed specifically for that pathway. The mutation is found in a significant proportion of hormone-receptor-positive, HER2-negative advanced breast cancers.
How is the PIK3CA mutation tested for?
Testing is done on tumour tissue — usually the biopsy sample you have already had — using next-generation sequencing, which reads the genetic code of the cancer cells. If tissue is limited or a repeat biopsy would be difficult, a liquid biopsy is an alternative: a blood test that detects fragments of tumour DNA circulating in the bloodstream. Your oncologist will tell you which approach suits your situation. Results generally take one to two weeks from when the sample reaches the laboratory, though specialist referrals can take longer.
Does a PIK3CA mutation mean the cancer is more aggressive?
No. The presence of the mutation tells your oncologist which molecular pathway is driving the tumour — it is not a statement about how fast-growing the cancer is or about your overall outlook. The stage, how far the cancer has spread, and how it has responded to earlier treatment are what determine urgency and prognosis. What the mutation result does is direct the treatment choice: when it is present, alpelisib becomes an option; when it is absent, a different treatment is chosen. The result is useful information, not a cause for alarm on its own.
How long do patients stay on alpelisib?
There is no fixed duration. Treatment continues for as long as the cancer is responding and side effects are manageable. Your team assesses this through regular blood tests and periodic imaging. If the cancer progresses or side effects cannot be brought to an acceptable level with dose adjustments, your oncologist will discuss changing the regimen. Some people remain on this treatment for many months; for others the timeline is shorter. Both outcomes happen, and close monitoring is what allows the right decision to be made at the right time.
Can I take alpelisib if I already have diabetes?
Having diabetes does not automatically rule out alpelisib, but it requires careful preparation. Your oncologist will review your current blood sugar control and HbA1c before starting, and may adjust your diabetes medicines in advance. Once treatment begins, blood sugar monitoring becomes more frequent. If blood sugar rises and cannot be brought to an acceptable level despite adjustments, your oncologist may decide the risk outweighs the expected benefit. This is an important conversation to have before treatment starts — share your full diabetes treatment history with your oncologist.
Is alpelisib available at CION?
CION centres coordinate access to targeted therapies including PI3K inhibitors as part of advanced breast cancer treatment planning. Eligibility is confirmed after biomarker testing and a full review of your treatment history, current health, and blood sugar profile. CION does not provide CAR-T or cell therapies; if those are being considered, you would be referred to a centre that offers them. For questions about alpelisib availability at your nearest CION location, the treating team is the right first contact.